ABC2, CaP CURE and Ingenuity Systems Kick Off Program to Identify Novel Uses for Existing Cancer Drugs


Mountain View, California, April 1, 2003 – ABC2, CaP CURE and Ingenuity Systems announced today a partnership that will test existing chemotherapeutic agents against recently discovered gene defects associated with prostate and brain cancer pathways. Leading researchers from Cedars-Sinai Medical Center, University of Michigan, University of California, San Francisco, and University of California, Los Angeles will participate in the program.

“Through a better understanding of how cancer pathways interact, we expect to be able to take existing drugs and in a fraction of the time compared to novel compounds, be able to demonstrate new ways to enhance patient care,” stated Dr. David Agus of Cedars-Sinai Medical Center.

The research teams will apply Ingenuity’s Pathways Knowledge Base, the world’s largest curated, computable model of biological pathways, representing a network of millions of individually modeled interrelationships between genes, proteins, cellular processes, tissues, small molecules, and disease. The scientists will navigate the database using Ingenuity’s pathways software, which delivers biologic insights from researchers. experimental data by computationally discerning disease pathways de novo from genomic data.

“We are pleased to be funding research and making it available to the community through this partnership. By leveraging these truly unique assets in combination with world-leading clinical researchers, we believe that we are creating opportunities to quickly bring new treatment paradigms to cancer patients,” commented John Reher, executive director of ABC2.

“This project allows us to better understand which genetic pathways are active in these specific cancers and which approved or late-stage, experimental drugs may prove useful in disrupting these pathways,” stated Howard Soule, executive vice president and chief science officer of CaP CURE, which helps to support Dr. Agus. research at Cedars-Sinai.

“In concert with these renowned organizations and distinguished researchers, we are forging a new path in the application of systems biology in mitigating the effects of brain and prostate cancers,” stated Jake Leschly, president and chief executive officer of Ingenuity.

About ABC2

Dan and Steve Case and their families, along with leading scientists and entrepreneurs, founded ABC2 in May 2001. ABC2 aims to raise awareness about brain cancer and help mobilize critical scientific research through research grants and partnerships. Each year more than 17,000 people in the United States find out that they have a primary brain tumor. An additional 100,000 patients are diagnosed with a brain tumor that has metastasized from another part of the body. ABC2‘s mission is to accelerate a cure for brain cancer by increasing the number of potential therapies discovered and then rapidly moving them into the clinic to help patients. In order to accelerate progress in what has been an under-served field of research, ABC2 provides researchers from all backgrounds with the support they need to make critical breakthroughs in brain cancer research.

About CaP CURE

CaP CURE, the Prostate Cancer Foundation, is the largest non-governmental source of funding to support research on the prevention, treatment and cure of prostate cancer. Since its inception in 1993, CaP CURE has funded more than $120 million to over 1,000 projects in over 100 cancer research centers, and continues to search for sure cures and controls that will eliminate prostate cancer as a life-threatening illness for men and their families.

Diagnosed in over 220,000 American men each year . one every 3 minutes . prostate cancer is the most commonly detected non-skin cancer in the United States. Additionally, the disease kills over 30,000 men in the United States each year. Prostate cancer is the second leading cause of cancer death in American men.

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View,